New hepatitis C drugs are very costly and unavailable to many state prisoners

Health Affairs

Volumn 35, Issue 10, 2016, Pages 1893-1901

  Beckman, Adam L ^a   Bilinski, Alyssa ^b   Boyko, Ryan ^a   Camp, George M ^c   Wall, A T ^d   Lim, Joseph K ^e   Wang, Emily A ^e   Bruce, R Douglas ^e,f   Gonsalves, Gregg S ^a  

^a YALE UNIVERSITY   (United States)

^b HARVARD UNIVERSITY   (United States)

^c Association of State Correctional Administrators   (United States)

^d RHODE ISLAND DEPARTMENT OF CORRECTIONS   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f South Central Rehabilitation Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; LEDIPASVIR PLUS SOFOSBUVIR; SOFOSBUVIR; SOFOSBUVIR PLUS VELBATASVIR; UNCLASSIFIED DRUG; BENZIMIDAZOLE DERIVATIVE; FLUORENE DERIVATIVE; LEDIPASVIR, SOFOSBUVIR DRUG COMBINATION; URIDINE PHOSPHATE;

ARTICLE; DRUG COST; DRUG INDUSTRY; GOVERNMENT; HEPATITIS C; HUMAN; PRISONER; PURCHASING; ADULT; ANALOGS AND DERIVATIVES; ECONOMICS; FEMALE; MALE; NORTH CAROLINA; ORGANIZATION AND MANAGEMENT; PRISON; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; UNITED STATES;

ADULT; ANTIVIRAL AGENTS; BENZIMIDAZOLES; FEMALE; FLUORENES; HEPATITIS C; HUMANS; MALE; NORTH CAROLINA; PRISONERS; PRISONS; RETROSPECTIVE STUDIES; STATE GOVERNMENT; UNITED STATES; URIDINE MONOPHOSPHATE;

EID: 84994234383     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2016.0296     Document Type: Article

References (34)

1. Denniston MM, Jiles RB, Drobeniuc J, Klevens RM, Ward JW, McQuillan GM, et al. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med. 2014;160(5):293-300.
2. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999. through 2002. Ann Intern Med. 2006;144(10):705-14.
3. Centers for Disease Control and Prevention. Surveillance for viral hepatitis-United States, 2011 [Internet]. Atlanta (GA): CDC; [last updated 2015 May 20; cited 2016 Aug 9]. Available from: http://www.cdc.gov/hepatitis/statistics/2011surveillance/commentary.htm.
4. Ly KN, Hughes EM, Jiles RB, Holmberg SD. Rising mortality associated with hepatitis C virus in the United States, 2003-2013. Clin Infect Dis. 2016;62(10):1287-8.
5. Varan AK, Mercer DW, Stein MS, Spaulding AC. Hepatitis C seroprevalence among prison inmates since 2001: still high but declining. Public Health Rep. 2014;129(2):187-95.
6. He T, Li K, Roberts MS, Spaulding AC, Ayer T, Grefenstette JJ, et al. Prevention of hepatitis C by screening and treatment in U.S. prisons. Ann Intern Med. 2016;164(2):84-92.
7. Harrison PM, Beck AJ. Prisoners in 2002. [Internet]. Washington (DC): Bureau of Justice Statistics; [revised 2003. Aug 27; cited 2016 Aug 9]. (Bulletin No. NCJ 200248). Available from: http://www.bjs.gov/content/pub/pdf/p02.pdf.
8. Spaulding AC, Weinbaum CM, Lau DT-Y, Sterling R, Seeff LB, Margolis HS, et al. A framework for management of hepatitis C in prisons. Ann Intern Med. 2006;144(10):762-9.
9. Martin NK, Vickerman P, Grebely J, Hellard M, Hutchinson SJ, Lima VD, et al. Hepatitis C virus treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-acting antivirals. Hepatology. 2013;58(5):1598-609.
10. Rich JD, Allen SA, Williams BA. Responding to hepatitis C through the criminal justice system. N Engl J Med. 2014;370(20):1871-4.
11. Rich JD, Allen SA, Williams BA. The need for higher standards in correctional healthcare to improve public health. J Gen Intern Med. 2015;30(4):503-7.
12. Estelle v. Gamble, 429 U.S. 97 (1976).
13. Spaulding AS, Kim AY, Harzke AJ, Sullivan JC, Linas BP, Brewer A, et al. Impact of new therapeutics for hepatitis C virus infection in incarcerated populations. Top Antivir Med. 2013;21(1):27-35.
14. Beck AJ, Maruschak LM. Hepatitis testing and treatment in state prisons [Internet]. Washington (DC): Bureau of Justice Statistics; 2004 Apr [cited 2016 Aug 9]. (Special Report No. NCJ 199173C). Available from: http://www.bjs.gov/content/pub/pdf/httsp.pdf.
15. Spaulding A, Greene C, Davidson K, Schneidermann M, Rich J. Hepatitis C in state correctional facilities. Prev Med. 1999;28(1):92-100.
16. Coalition of Correctional Health Authorities, American Correctional Association. Hepatitis C in correctional settings: challenges and op-portunities [Internet]. Alexandria (VA): ACA; 2015 Apr [cited 2016 Aug 9]. Available from: http://www.aca.org/ACA_PROD_IMIS/Docs/OCHC/HCVinCorrectional Setting_Final.pdf.
17. Liang TJ, Ghany MG. Current and future therapies for hepatitis C virus infection. N Engl J Med. 2013; 368(20):1907-17.
18. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368(20):1878-87.
19. Lawitz E, Poordad FF, Pang PS, Hyland RH, Ding X, Mo H, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet. 2014; 383(9916):515-23.
20. Feld JJ, Jacobson IM, Hézode C, Asselah T, Ruane PJ, Gruener N, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015; 373(27):2599-607.
21. Liu S, Watcha D, Holodniy M, Goldhaber-Fiebert JD. Sofosbuvirbased treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations: a cost-effectiveness analysis. Ann Intern Med. 2014;161(8): 546-53.
22. Federal Bureau of Prisons. Evaluation and management of chronic hepatitis C virus (HCV) infection [Internet]. Washington (DC): BOP; 2016. Apr [cited 2016 Aug 9]. (Clinical Practice Guidelines). Available from: https://www.bop.gov/resources/pdfs/hepatitis_c.pdf.
23. Hoofnagle JH, Sherker AH. Therapy for hepatitis C-the costs of success. N Engl J Med. 2014;370(16):1552-3.
24. Editorial Board. Costly hepatitis C drugs for everyone? New York Times. 2015 Sep 2.
25. Moorjani H, Koenigsmann C, Kim MJ, Spaulding AC. Prisoners treated for hepatitis C with protease inhibitor, New York, USA, 2012. Emerg Infect Dis. 2015;21(1):186-8.
26. Carson EA. Prisoners in 2014 [Internet]. Washington (DC): Bureau of Justice Statistics; 2015 Sep 17 [cited 2016. Aug 16]. Available from: http://www.bjs.gov/index.cfm?ty= pbdetail&iid=5387.
27. Centers for Disease Control and Prevention. Hepatitis C FAQs for health professionals [Internet]. Atlanta (GA): CDC; [last updated 2016 Jul 21; cited 2016 Aug 9]. Available from: http://www.cdc.gov/hepatitis/hcv/hcvfaq.htm.
28. US Senate Committee on Finance. The price of Sovaldi and its impact on the U.S. health care system [Internet]. Washington (DC): The Senate; 2015. Dec [cited 2016 Aug 9]. Available from: http://www.finance.senate.gov/imo/media/doc/1%20 The%20Price%20of%20Sovaldi %20and%20Its%20Impact%20on %20the%20U.S.%20Health%20 Care%20System%20(Full%20 Report).pdf.
29. Seeking Alpha. Gilead Sciences' (GILD) CEO John Martin on Q4 2014. results-earnings call transcript. Seeking Alpha [serial on the Internet]. 2015 Feb 3 [cited 2016 Aug 16]. Available from: http://seekingalpha.com/article/2880996-gilead-sciences-gild-ceo-johnmartin-on-q4-2014-results-earningscall-transcript?part=single.
30. Trooskin SB, Reynolds H, Kostman JR. Access to costly new hepatitis C drugs: medicine, money, and advocacy. Clin Infect Dis. 2015;61: 1825-30.
31. Government Accountability Office. Drug pricing: manufacturer discounts in the 340B Program offer benefits, but federal oversight needs improvement [Internet]. Washington (DC): GAO; 2011 Sep [cited 2016 Aug 9]. (Report No. GAO-11-836). Available from: http://www.hrsa.gov/opa/programrequirements/reports/gaooversightneeded 09232011.pdf.
32. Beckwith CG, Kurth AE, Bazerman L, Solomon L, Patry E, Rich JD, et al. Survey of US correctional institutions for routine HCV testing. Am J Public Health. 2015;105(1):68-71.
33. Graham J. Medicaid, private insurers begin to lift curbs on pricey hepatitis C drugs. Kaiser Health News [serial on the Internet]. 2016 Jul 5 [cited 2016. Aug 9]. Available from: http://khn.org/news/medicaid-privateinsurers-begin-to-lift-curbs-onpricey-hepatitis-c-drugs/.
34. Barua S, Greenwald R, Grebely J, Dore GJ, Swan T, Taylor LE. Restrictions for Medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States. Ann Intern Med. 2015;163(3):215-23.